Lack of clinical and histological progression of chronic hepatitis C in individuals with true persistently normal ALT: The result of a 17-year follow-up

Journal of Viral Hepatitis

Volumn 20, Issue 4, 2013, Pages

  Nunnari, G ^a,b   Pinzone, M R ^a   Cacopardo, B ^a  

^a UNIVERSITY OF CATANIA   (Italy)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

chronic hepatitis; disease progression; fibrosis; HCV; PNALT

Indexed keywords

ALANINE AMINOTRANSFERASE; PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; PEGINTERFERON ALPHA2B PLUS RIBAVIRIN; PERSISTENTLY NORMAL ALANINE AMINOTRANSFERASE; UNCLASSIFIED DRUG;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DECOMPENSATED LIVER CIRRHOSIS; DISEASE COURSE; FEMALE; FOLLOW UP; GENOTYPING TECHNIQUE; HEPATITIS C; HUMAN; HUMAN TISSUE; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCORING SYSTEM; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; ALANINE TRANSAMINASE; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HEPATITIS C, CHRONIC; HUMANS; LIVER; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX;

EID: 84875215326     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12029     Document Type: Article

References (31)

1. Puoti C, Castellacci R, Montagnese F, et al,. Histological and virological features and follow-up of hepatitis C virus carriers with normal aminotransferase levels: the Italian prospective study of the asymptomatic C carriers (ISACC). J Hepatol 2002; 37 (1): 117-123.
2. Marcellin P, Lévy S, Erlinger S,. Therapy of hepatitis C: patients with normal aminotransferase levels. Hepatology 1997; 26 (3 Suppl 1): 133S-136S.
3. Tassopoulos NC,. Treatment of patients with chronic hepatitis C and normal ALT levels. J Hepatol 1999; 31 (S1): 193-196.
4. Zapata R,. Clinical approach to the patient with chronic hepatitis C infection and normal aminotransferases. Ann Hepatol 2010; 9: 72-79.
5. Strader DB, Wright T, Thomas DL, Seeff LB, American Association for the Study of Liver Diseases. Diagnosis, management and treatment of hepatitis C. AASLD practice guideline. Hepatology 2004; 39: 1147-1471.
6. Ghany MG, Strader DB, Thomas DL, Seeff LB, American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335-1373.
7. Puoti C, Guido M, Mangia A, Persico M, Prati D, Committee on HCV carriers with normal alanine aminotransferase levels of the Italian Association for the Study of the Liver. Clinical management of HCV carriers with normal aminotransferase levels. Dig Liver Dis 2003; 35 (5): 362-369.
8. Lawson A,. Trent Hepatitis C Study Group. Hepatitis C virus-infected patients with a persistently normal alanine aminotransferase: do they exist and is this really a group with mild disease? J Viral Hepat 2010; 17: 51-58.
9. Puoti C, Magrini A, Stati T, et al,. Clinical, histological and virological features of hepatitis C virus carriers with persistently normal or abnormal alanine transaminase levels. Hepatology 1997; 26 (6): 1393-1398.
10. Calvaruso V, Craxì A,. Implication of normal liver enzymes in liver disease. J Viral Hepat 2009; 16 (8): 529-536.
11. Rumi MG, De Filippi F, La Vecchia C, et al,. Hepatitis C reactivation in patients with chronic infection with genotype 1b and 2c: a retrospective color study of 206 untreated patients. Gut 2005; 54 (3): 402-406.
12. Okanoue T, Makiyama A, Nakayama M, et al,. A follow-up study to determine the value of liver biopsy and need for antiviral therapy for hepatitis C virus carriers with persistently normal serum aminotransferase. J Hepatol 2005; 43 (4): 599-605.
13. Hui CK, Belaye T, Montegrande K, Wright TL,. A comparison in the progression of liver fibrosis in chronic hepatitis C between persistently normal and elevated transaminase. J Hepatol 2003; 38 (4): 511-517.
14. Shiffman ML, Diago M, Tran A, et al,. Chronic hepatitis C in patients with persistently normal alanine transaminase levels. Clin Gastroenterol Hepatol 2006; 4 (5): 645-652.
15. Persico M, Persico E, Suozzo R, et al,. Natural history of hepatitis C virus carriers with persistently normal aminotransferase levels. Gastroenterology 2000; 118 (4): 760-764.
16. Martinot-Peignoux M, Boyer N, Cazals-Hatem D, et al,. Prospective study on anti-hepatitis C virus-positive patients with persistently normal serum alanine transaminase with or without detectable serum hepatitis C virus RNA. Hepatology 2001; 34 (5): 1000-1005.
17. Cividini A, Rebucci C, Silini E, Modelli MU,. Is the natural history of HCV carriers with normal aminotransferase levels really benign? Gastroenterology 2001; 121: 1526-1527.
18. Alberti A,. Towards more individualized management of hepatitis C virus patients with initially or persistently normal alanine aminotransferase levels. J Hepatol 2005; 42: 266-274.
19. Alberti A, Benvegnu L, Boccato S, Ferrari A, Sebastiani G,. Natural history of initially mild chronic hepatitis C. Dig Liver Dis 2004; 36 (10): 646-654.
20. Puoti C, Bellis L, Martellino F, et al,. Occurrence of HCC in a apparently 'healthy' HCV carrier. Eur J Gastroenterol Hepatol 2005; 17: 1263-1264.
21. Kumada T, Toyoda H, Kiriyama S, et al,. Incidence of hepatocellular carcinoma in hepatitis C carriers with normal alanine aminotransferase levels. J Hepatol 2009; 50 (4): 729-733.
22. Bedossa P,. Presentation of a grid for computer analysis for compilation of histopathologic lesions in chronic viral hepatitis C. Cooperative study of the METAVIR group. Ann Pathol 1993; 13 (4): 260-265.
23. Hand D, Crowder M,. Practical Longitudinal Data Analysis. London: Chapman & Hall, 1996.
24. Maio G, d'Argenio P, Stroffolini T, et al,. Hepatitis C virus infection and alanine transaminase levels in the general population: a survey in a Southern Italian town. J Hepatol 2000; 33 (1): 116-120.
25. Guadagnino V, Stroffolini T, Rapicetta M, et al,. Prevalence, risk factors, and genotype distribution of hepatitis C virus infection in the general population: a community-based survey in southern Italy. Hepatology 1997; 26 (4): 1006-1011.
26. Puoti C, Bellis L, Guarisco R, Dell'Unto O, Spilabotti L, Costanza OM., HCV carriers with normal alanine aminotransferase levels: healthy persons or severely ill patients? Dealing with an everyday clinical problem. Eur J Intern Med 2010; 21 (2): 57-61.
27. Puoti C, Guarisco R, Spilabotti L, et al,. Should we treat HCV carriers with normal ALT levels? The "5Ws" dilemma. J Viral Hepat 2012; 19: 229-235.
28. Di Stefano R, Stroffolini T, Ferraro D, et al,. Endemic hepatitis C virus infection in a Sicilian town: further evidence for iatrogenic transmission. J Med Virol 2002; 67 (3): 339-344.
29. Persico M, Perrotta S, Persico E, et al,. Hepatitis C virus carriers with persistently normal ALT levels: biological peculiarities and update of the natural history of liver disease at 10 years. J Viral Hepat 2006; 13 (5): 290-296.
30. Mathurin P, Moussalli J, Cadranel JF, et al,. Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity. Hepatology 1998; 27: 868-872.
31. Craxì A, Pawlotsky M, Wedemeyer H, et al,. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2011; 55 (2): 245-264.